News
The amended dosing regimen was approved based on results from a post hoc analysis of the phase 2 MagnetisMM-3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback